Share: PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER'S DISEASE MET ITS PRIMARY ENDPOINT MASITINIB DEMONSTRATED SIGNIFICANT EFFECT ON BOTH COGNITION, MEASURED WITH ADAS-COG, AND DAILY ACTIVITY, MEASURED WITH ADCS-ADL AB SCIENCE WILL HOST A LIVE WEBCAST ON DECEMBER 17, 2020 - 11am-12am EST; 5pm-6pm CET WITH KEY OPINION LEADERS TO FURTHER DISCUSS THE RESULTS Paris, December 16, 2020, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the Phase 2B/3 study (AB09004 - NCT01872598) evaluating oral masitinib in patients with mild and moderate Alzheimer's disease met its predefined primary endpoint. Study AB09004 was an international, randomized, placebo-controlled, phase 2B/3 study evaluating different doses of masitinib as a treatment of patients with confirmed mild to moderate Alzheimer's disease. This study compared the efficacy and safety of masitinib relative to placebo after 24 weeks of treatment when administered as an add-on therapy to cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine. Two doses of masitinib were tested, masitinib 4.5 mg/kg/day and a titrated dose of masitinib from 4.5 to 6.0 mg/kg/day, with each dose having an independent control arm.